Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 31:12:792227.
doi: 10.3389/fneur.2021.792227. eCollection 2021.

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Artur Schumacher-Schuh  1   2 , Andrei Bieger  3 , Wyllians V Borelli  2 , Makayla K Portley  4 , Paula Saffie Awad  5 , Sara Bandres-Ciga  4   6
Affiliations
Review

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Artur Schumacher-Schuh et al. Front Neurol. .

Abstract

Proteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting or reversing the neurodegenerative process. This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases. We focus on the most common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We discuss the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery. We critically review advancements made so far, highlighting how metabolomics and proteomics may have a significant impact in future therapeutic and biomarker development. Finally, we further outline technologies used so far as well as challenges and limitations, placing the current information in a future-facing context.

Keywords: AD; ALS; Alzheimer's disease; PD; Parkinson's disease; amyotrophic lateral sclerosis; metabolomics; proteomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Metabolites and Proteins across Neurodegenerative Diseases. Green, red, and blue circles highlight major metabolites and proteins nominated by research studies as implicated in amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease etiology.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and transcriptomic biomarkers in neurodegenerative diseases: current situation and the road ahead. Cells. (2021) 10:1030. 10.3390/cells10051030 - DOI - PMC - PubMed
    1. Walker DI, Valvi D, Rothman N, Lan Q, Miller GW, Jones DP. The metabolome: a key measure for exposome research in epidemiology. Curr Epidemiol Rep. (2019) 6:93–103. 10.1007/s40471-019-00187-4 - DOI - PMC - PubMed
    1. Wishart DS. Current progress in computational metabolomics. Brief Bioinform. (2007) 8:279–93. 10.1093/bib/bbm030 - DOI - PubMed
    1. Emwas A-HM. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol Biol. (2015) 1277:161–93. 10.1007/978-1-4939-2377-9_13 - DOI - PubMed
    1. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, et al. . HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. (2018) 46:D608–17. 10.1093/nar/gkx1089 - DOI - PMC - PubMed